NCT00628290View on ClinicalTrials.gov

Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

November 30, 2004

Study Completion Date

March 31, 2008

Conditions
Schizophrenia
Interventions
DRUG

Cannabidiol

Capsules, 3 times daily, 200 mg, 4 weeks

DRUG

Amisulpride

Capsules, 3 times daily, 200 mg, 4 weeks

Trial Locations (1)

50924

University of Cologne, Dept. of Psychiatry and Psychotherapy, Cologne

All Listed Sponsors
lead

University of Cologne

OTHER

NCT00628290 - Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis | Biotech Hunter | Biotech Hunter